NXPI vs SPRY · P/E 29, rev $12.27B vs rev $56.3M
NXP Semiconductors NV (NXPI) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
NXP Semiconductors NV (NXPI) is a semiconductors company listed on NASDAQ.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported NXPI revenue for 2025-12-31 was $12.27B. Net income was $2.02B. Revenue was down 2.7% from 2024-12-31 to 2025-12-31. NXPI currently screens at market cap $76.47B and trailing P/E 29.0.
Latest reported SPRY revenue for 2026-06-30 was $56.3M. Net income was -$123.0M. SPRY currently screens at market cap $983.1M.
NXPI currently screens at market cap $76.47B and trailing P/E 29.0. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the NXPI and SPRY stock pages for the full models.
Not investment advice.